LONDON, April 1, 2017 /PRNewswire/ -- LivaNova PLC
(NASDAQ:LIVN; LSE: LIVN) ("LivaNova" or the "Company"), a
market-leading medical technology and innovation company, today
announced it is reiterating its full-year 2017 guidance published
on March 1, 2017, and the company
undertakes no duty to update for subsequent events.
LivaNova expects worldwide net sales for full-year 2017 to grow
between 1 and 3 percent on a constant-currency basis. Adjusted
diluted earnings per share for 2017 are expected to be in the range
of $3.25 to $3.45.
About LivaNova
LivaNova PLC is a global medical technology company built on
nearly five decades of experience and a relentless commitment to
improve the lives of patients around the world. LivaNova's advanced
technologies and breakthrough treatments provide meaningful
solutions for the benefit of patients, healthcare professionals and
healthcare systems. Headquartered in London and with a presence in more than 100
countries worldwide, the company employs more than 4,500 employees.
LivaNova operates as three business franchises: Cardiac
Surgery, Neuromodulation and Cardiac Rhythm Management, with
operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit
www.LivaNova.com.